Skip to main content
SpringerLink
Log in

Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy

  • Short Communication
  • Published:
Targeted Oncology Aims and scope Submit manuscript

Abstract

Background

Over the past few years, data have suggested that severe peripheral arterial occlusive disease (PAOD) is associated with nilotinib exposure. However, the characteristics of this adverse drug reaction are poorly described since its frequency is low. As far as we know, no study using a spontaneous adverse drug reactions reporting system was performed to describe the characteristics of cases of PAOD related to nilotinib.

Objective

We performed a study to describe the cardiovascular risk profile of cases of PAOD in patients treated with nilotinib spontaneously reported to the French Pharmacovigilance Database (FPVD).

Patients/Methods

We selected all cases of “vascular disorders,” as the System Organ Class in MedDRA®, in which nilotinib was “suspected” and recorded in the French Pharmacovigilance Database between 2007 and 21 October 2014. We then identified cases of PAOD with a Low Level Term and through a detailed summary of the clinical description.

Results

We identified 25 cases of POAD. Most of the patients were older than 60 years (84 %) or had another cardiovascular risk factor such as hypercholesterolemia, arterial hypertension, overweight/obesity, smoking, or diabetes mellitus (72 %). Females (13 cases) and males (12 cases) were equally represented, but the presence of cardiovascular risk factors was more frequent in females than in males. The mean time from initiation of nilotinib to PAOD onset was 24 months and was significantly longer in patients aged less than 60 years compared with those aged over 60 years (33.8 ± 24.6 months vs. 22.6 ± 17.5 months, p = 0.002). Pre-existing cardiovascular risk factors, especially diabetes mellitus, also seem to accelerate its occurrence.

Conclusions

The FPVD is a useful tool in describing the cardiovascular risk profile of patients with PAOD during nilotinib exposure. Physicians have to be particularly vigilant in patients older than 60 years of age; in patients younger than 60 years of age, long-term surveillance has to be maintained.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Aichberger KJ, Herndlhofer S, Schernthaner G-H, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533–9.

    Article  CAS  PubMed  Google Scholar 

  2. Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103:1347–8.

    Article  PubMed  Google Scholar 

  3. Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337–40.

    Article  PubMed  Google Scholar 

  4. Levato L, Cantaffa R, Kropp MG, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90:531–2.

    Article  CAS  PubMed  Google Scholar 

  5. Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316–21.

    Article  CAS  PubMed  Google Scholar 

  6. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27:1310–5.

    Article  CAS  PubMed  Google Scholar 

  7. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86:610–1.

    Article  PubMed  Google Scholar 

  8. Spreux A, Baldin B, Chichmanian RM. Pharmacovigilance in practice. Transfus Clin Biol. 1999;6:254–9.

    Article  CAS  PubMed  Google Scholar 

  9. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–17.

    Article  CAS  PubMed  Google Scholar 

  10. Begaud B, Evreux JC, Jouglard J, et al. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie. 1985;40:111–8.

    CAS  PubMed  Google Scholar 

  11. Montastruc J-L, Sommet A, Lacroix I, et al. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Joint Bone Spine. 2006;73:629–32.

    Article  PubMed  Google Scholar 

  12. Valent P, Hadzijusufovic E, Schernthaner G-H, et al. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood. 2015;125:901–6.

    Article  CAS  PubMed  Google Scholar 

  13. Ouriel K. Peripheral arterial disease. Lancet. 2001;358:1257–64.

    Article  CAS  PubMed  Google Scholar 

  14. Vray M, Chwalow J, Charansonney O, et al. National study of obliterative arterial disease of the lower limbs involving general practitioners in France: Artemio study. J Cardiovasc Pharmacol. 1995;25 Suppl 2:S51–7.

    Article  CAS  PubMed  Google Scholar 

  15. Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055–63.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Dr Laurence Legros (CHU Nice), Pr Antoine Thyss (Centre Antoine Lacassagne, Nice), Dr Emmanuel Petit (Clinique Oxford, Cannes), the National Research Agency (Paris).

Author information

Authors and Affiliations

  1. Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, Pharmacoépidémiologie et Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, CHU Toulouse, Faculté de Médecine de l’Université de Toulouse, Toulouse, France

    E. Bondon-Guitton, H. Bagheri & J. L. Montastruc

  2. Centre Régional de Pharmacovigilance de Bourgogne, Centre Hospitalier Universitaire, Dijon, France

    S. Combret

  3. Pharmacologie Clinique et Vigilances, Centre Hospitalier Universitaire, Poitiers, France

    M. C. Pérault-Pochat

  4. Centre Régional de Pharmacovigilance, Hôpital de Cimiez, Nice, France

    M. Stève-Dumont

  5. Service d’Hématologie, Institut Universitaire du Cancer, Toulouse, France

    F. Huguet

  6. Service de Pharmacologie Médicale et Clinique, CHU Toulouse, Faculté de Médecine de l’Université de Toulouse, Toulouse, France

    F. Despas & A. Pathak

Authors
  1. E. Bondon-Guitton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Combret
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. C. Pérault-Pochat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Stève-Dumont
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H. Bagheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Huguet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. Despas
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Pathak
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. L. Montastruc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Bondon-Guitton.

Ethics declarations

Funding

This work was supported by the National Research Agency (ANR: Agence Nationale de la Recherche) for the “investissement d’avenir” (ANR-11-PHUC-001). The funding allowed the development of the CAPTOR program (Cancer Pharmacology of Toulouse-Oncopole and Region) and performance of the present study.

Conflicts of Interest

EB-G, SC, MCP-P, MS-D, HB, FH, FD, AP and JLM declare no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bondon-Guitton, E., Combret, S., Pérault-Pochat, M.C. et al. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Targ Oncol 11, 549–552 (2016). https://doi.org/10.1007/s11523-016-0417-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-016-0417-x

Keywords

Search

Navigation